Clinical Trial

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This early phase (Phase 1) study will evaluate BRII 5395, administered in combination with two approved anticancer agents, sintilimab and bevacizumab, in patients with advanced liver cancer caused by chronic hepatitis B virus (HBV) infection. The primary objective of the study is to assess the safety and tolerability of the combination therapy, as well as to explore preliminary evidence of clinical benefit.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-23.
Trial Details
NCT Number NCT07557251
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Advanced HBV-Related Hepatocellular Carcinoma
Enrollment 21 participants
Start Date 2026-05
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-06